Replies to post #323587 on Avid Bioservices Inc (CDMO)

[biopharm]

Flavia Pernasetti
Pfizer

Flavia Pernasetti another interesting one to keep an eye on, because as one of the collaborators with Pergrine PS Targeting researcher / biomarker discovery guru Dr Bruce D Freimark, we have a clear infringement upon PS Targeting it seems below, unless of course.....it is simply one of the non Disclosed collaborations that Steve King mentioned, as in dozens of collaborations and it leads somewhere special, because it looks like this Antibody (PF-06747143) = a PS Targeting antibody.

Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer

Irene Stasi and Federico Cappuzzo

Additional article information

Abstract
Bavituximab is a an unconjugated, chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the phosphatidylserine (PS) expressed on tumor endothelium, with a specific mechanism of action. PS is an anionic membrane phospholipid, physiologically restricted to the internal membrane leaflet; various pathophysiologic processes cause the exposure of PS on the external membrane leaflet. Bavituximab, once bound, starts up host effector activities, such as antibody dependent cellular cytotoxicity, causing vessel destruction and enhancing antitumor immunity. Phase I clinical trials of bavituximab administered as monotherapy or in combination with other chemotherapeutic agents in adults with pretreated solid tumors have been accomplished, indicating that bavituximab can be safely dispensed weekly, with a recommended dose of 1 and 3 mg/kg. A Phase II randomized, placebo-controlled trial of bavituximab plus docetaxel, in the second-line therapy setting of locally advanced or metastatic non-small-cell lung cancer, has been conducted and recently presented, suggesting a clinical benefit of the combination, with an overall response rate of 17% and median overall survival of more than 11 months. A Phase III trial is currently ongoing. Bavituximab has been studied in combination with platinum-based doublets with promising results. In the present paper we summarize the preclinical development and clinical experience with bavituximab in non-small-cell lung cancer.
....
....

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217514/

A Novel CXCR4 Antagonist IgG1 Antibody (PF-06747143) for the Treatment of Hematological Malignancies

Flavia Pernasetti, Shu-Hui Liu, Max Hallin, Yin Gu, Wei-Hsien Ho, Cathy Zhang, Bernadette Pascual, Brett Simmons, Zhengming Yan, Nanni Huser, Wenlian Wang, Justine Lam, Mary E Spilker, Eileen Blasi, Thomas-Toan Tran, Jyothirmayee Kudaravalli, Jing-Tyan Ma, Sherman Michael Chin, David Shelton, Tod Smeal and Valeria Fantin
Blood 2014 124:2311;
...
...Here we describe the generation of a highly potent and selective anti-CXCR4 humanized IgG1 antagonist Ab (PF-06747143) that binds to human CXCR4 with high affinity and blocks SDF-1-induced Calcium flux and cAMP signaling. We have also characterized the ability of PF-06747143 to induce cell death through three different mechanisms: a) mobilization of cells from CXCL12-rich niches, making them more sensitive to chemotherapy b) direct cell-death through a mechanism dependent on the antibody’s bivalency; c) ADCC- and CDC-dependent cell death through the Fc-region in IgG1 backbone, when in the presence of effector cells or serum proteins.
....
....
http://www.bloodjournal.org/content/124/21/2311?sso-checked=true

A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT02954653

PF 06747143
Alternative Names: PF-06747143
Mechanism of Action
Apoptosis stimulants; CXCR4 receptor antagonists; Immunomodulators
http://adisinsight.springer.com/drugs/800048241

......interesting, they don't disclose the full MOA but they do admit it is an Immunomodulator....damn, and when Steve King was in the house we are astronomical and gave details of the MOA vs Renegade Roger Lias reduced us to residual value.

Roger, you notice anything?? Maybe Pfizer says it is an "interesting" MOA because they are possibly infringing upon PS Targeting IP rights....that is under the new BODs control so be very careful not to drop a breadcrumb deal on anyone and while we are at it lets get some updates on trials like the Yervoy / Bavi 19 patients of 22 that I bet provides more safety, no off target TOXICITIES to be still relorted.

____________

Background: Bavituximab a first-in-class immunomodulator targeting phosphatidylserine (PS), a lipid externalized on tumor and endothelial cells.
http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.345